Cue Biopharma says CUE — 221 Phase 2 trial in chronic spontaneous urticaria meets primary endpoint
Cue Biopharma reported positive topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, meeting primary and key secondary goals. Responses strengthened beyond the main assessment window, with benefit persisting for months in the highest-dose group following treatment completion. Results suggested a differ